Renaissance Capital logo

Gossamer Bio Priced, Nasdaq: GOSS

Developing in-licensed immunotherapies for asthma and other indications.

Industry: Health Care

Latest Trade: $17.43 0.00 (0.0%)

First Day Return: +12.1%

Return from IPO: +8.9%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Our goal is to be an industry leader in each of these therapeutic areas and enhance and extend the lives of patients suffering from such diseases. To accomplish this goal, we have assembled a deeply experienced and highly skilled group of industry veterans, scientists, clinicians and key opinion leaders from leading biotechnology and pharmaceutical companies, as well as leading academic centers from around the world. Our collective immunology and translational discovery and development expertise serves as the foundation of our company. We currently have six programs: three clinical-stage product candidates and three preclinical programs. We commenced a Phase 2b clinical trial for our most advanced product candidate, GB001, in moderate-to-severe eosinophilic asthma in October 2018 and expect to conduct an interim analysis in the first half of 2020.
more less
IPO News for Gossamer Bio
more
IPO Data
IPO File Date 12/21/2018
Offer Price $16.00
Price Range $16.00 - $16.00
Offer Shares (mm) 17.3
Deal Size ($mm) $276
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/07/2019
Offer Price $16.00
Price Range $16.00 - $16.00
Offer Shares (mm) 17.3
Deal Size ($mm) $276
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters San Diego, CA
Founded 2015
Employees 105
Website www.gossamerbio.com